Brain Tumor Surgery — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

Brain tumor surgery, most commonly performed as a craniotomy, involves surgically removing or debulking a benign or malignant intracranial neoplasm to relieve raised intracranial pressure, control seizures, obtain tissue for histological and molecular diagnosis, and improve survival when combined with adjuvant radiotherapy and chemotherapy. The procedure involves temporarily removing a section of the skull (bone flap) to access the brain. Neurosurgeons use operating microscopes for magnification, neuronavigation systems (MRI-guided stereotactic mapping), intraoperative MRI to confirm extent of resection, and fluorescence-guided surgery using 5-aminolevulinic acid (5-ALA) to distinguish tumour tissue from normal brain. Brain tumours are classified by the WHO into grades I–IV, with grade IV glioblastoma (GBM) being the most aggressive. Treatment is multidisciplinary, with surgery the cornerstone of initial management for most accessible tumours. Biopsy alone (stereotactic or open) is performed for deep, inaccessible, or disseminated tumours unsuitable for gross total resection. Brain tumour surgery, most commonly performed as a craniotomy, involves surgically removing or debulking a benign or malignant intracranial neoplasm to relieve raised intracranial pressure, control seizures, obtain tissue for definitive histopathological and molecular diagnosis, and improve survival when combined with adjuvant therapy. Primary brain tumours include gliomas (glioblastoma multiforme, astrocytoma, oligodendroglioma), meningiomas, pituitary adenomas, and medulloblastomas; secondary (metastatic) tumours are more common than primary malignancies. Brain tumour surgery is performed by neurosurgeons. Approximately 85,000 primary brain and other CNS tumours are diagnosed in the United States annually, with glioblastoma (GBM) being the most common malignant type. Intraoperative technologies including fluorescence-guided surgery (5-ALA), intraoperative MRI, and neurophysiological monitoring have significantly improved tumour resection rates and functional preservation.

Brain tumor surgery is indicated for patients with surgically accessible intracranial tumours causing neurological deficits (weakness, aphasia, visual loss), raised intracranial pressure (headache, vomiting, papilloedema), new-onset seizures, or radiological progression. The most common indications include gliomas (grade II astrocytoma, oligodendroglioma, glioblastoma), meningiomas, brain metastases (particularly solitary lesions from lung, breast, or melanoma), pituitary adenomas (via transsphenoidal approach), acoustic neuromas (vestibular schwannomas), ependymomas, and medulloblastomas in children. Surgery is also used for stereotactic biopsy of deep thalamic, basal ganglia, or brainstem lesions where open resection is too risky. Not all brain tumours require immediate surgery — low-grade gliomas in eloquent areas may be observed with serial MRI. Multidisciplinary neuro-oncology team discussion determines the optimal treatment sequence for each patient. Brain tumour surgery is indicated for patients with surgically accessible intracranial tumours causing neurological deficits (weakness, aphasia, visual loss), raised intracranial pressure (headache, vomiting, altered consciousness), medically refractory seizures, or tumours demonstrating radiological progression. Surgery is the first step for obtaining histopathological and molecular tumour diagnosis (IDH mutation, 1p/19q codeletion, MGMT promoter methylation) required to guide adjuvant chemoradiotherapy. For glioblastoma, maximal safe surgical resection followed by the Stupp protocol (temozolomide and radiotherapy) is the standard of care. Complete surgical resection (Simpson grade I) is curative for many meningiomas. Patients with tumours in deep, eloquent, or brainstem locations, or with poor performance status, may be managed with stereotactic radiosurgery (Gamma Knife or CyberKnife), targeted biopsy, or best supportive care.

The patient is positioned with the head fixed in a Mayfield three-pin frame for rigidity. Under general anaesthesia (or awake for tumours in eloquent cortex governing speech or motor function), the scalp is incised and a bone flap removed with a craniotome. The brain is approached through a corridor of least resistance, retracted gently with cottonoids. Under the operating microscope, the tumour is identified and resected using suction, bipolar diathermy, and ultrasonic aspiration (CUSA). Neuronavigation (real-time MRI or CT overlay) guides the surgeon to respect anatomical boundaries. Fluorescence with 5-ALA causes GBM tissue to fluoresce pink under violet light, improving gross total resection rates. Intraoperative MRI (available at specialist centres) identifies residual tumour before wound closure. For awake craniotomy, the patient is kept conscious during tumour removal to perform language and motor tasks, allowing real-time cortical and subcortical mapping to preserve function. After resection, bone flap is replaced and secured with titanium plates. Surgery lasts 3–8 hours. The patient is positioned with the head fixed in a Mayfield three-pin skull clamp for rigidity. Under general anaesthesia (or awake craniotomy for tumours adjacent to eloquent cortex governing speech or motor function), the scalp is infiltrated with local anaesthetic and the skin incision planned based on neuronavigation to the tumour coordinates. A bone flap is elevated using a craniotome, and the dura opened with a cruciate or curvilinear incision. The surgical corridor is established using an operating microscope, brain retractors or dynamic retraction (cortical mapping to identify eloquent areas), and the tumour distinguished from normal brain by texture, colour, and vascularity. Intraoperative ultrasound or MRI may confirm the extent of resection in real-time. The dura is closed watertight with sutures and a dural graft if required; the bone flap is replaced and secured with titanium plates and screws. Intraoperative neuromonitoring (somatosensory evoked potentials, motor evoked potentials, and awake mapping) protects function throughout. Procedure duration is 3–8 hours depending on tumour size, location, and vascularity.

Surgical resection provides tissue for definitive WHO histological and molecular classification (IDH mutation, MGMT methylation, 1p/19q co-deletion), which directly determines prognosis and treatment. Gross total resection of meningioma achieves 90–95% 10-year local control rate. Extent of resection in glioblastoma correlates with survival: patients achieving greater than 98% volumetric resection have median survival of 16–21 months compared with 11–14 months for subtotal resection, with temozolomide and radiotherapy. 5-ALA fluorescence-guided surgery increases rates of complete resection in glioblastoma from 36% to 65% (JAMA 2006 RCT). Single brain metastasis resection combined with radiotherapy improves 1-year survival significantly compared to radiotherapy alone. Tumour debulking in high-grade glioma improves quality of life by relieving headache, seizures, and neurological deficits even when complete resection is not achievable.

Brain tumour surgery carries significant but quantifiable risks that vary with tumour location, size, and proximity to eloquent structures. New or worsened neurological deficit occurs in 10–30% of patients depending on tumour location, with the majority showing partial or complete recovery within 3–6 months. Specific deficits include motor weakness, aphasia, visual field loss, or cognitive changes. Surgical site infection (wound or deep brain abscess) affects 2–4% of patients. Intracerebral haemorrhage requiring reoperation occurs in approximately 2–5%. Cerebral oedema is managed with perioperative dexamethasone. Cerebrospinal fluid leak, meningitis, seizures, DVT, and pulmonary embolism are further risks. Mortality from elective craniotomy at experienced centres is below 1–2% for accessible supratentorial tumours; higher for posterior fossa tumours and emergency procedures. Pre-operative neuropsychological testing and functional MRI mapping help predict and minimise neurological risk.

After brain tumour surgery, patients are admitted to a neurosurgical ICU or high-dependency unit for 24–48 hours for neurological observations (GCS, pupil response, motor function). Dexamethasone reduces perioperative cerebral oedema and is tapered over 7–14 days. Antiepileptic drugs are continued or initiated as appropriate. Hospital stay is typically 3–7 days for supratentorial procedures; longer for posterior fossa surgery. MRI with gadolinium contrast is performed within 24–72 hours to assess extent of resection before granulation tissue forms. Formal neurological and neuropsychological rehabilitation begins during admission and continues as an outpatient. Most patients return to light activities at 4–6 weeks. Return to driving requires seizure-free periods per national regulations (typically 6–12 months after intracranial surgery for tumour). Adjuvant radiotherapy and chemotherapy typically begin 4–6 weeks post-operatively. Oncology follow-up with serial MRI continues indefinitely.